Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
letter
. 1986 Sep;78(9):811–821.

When Should Sarcoidosis Be Treated?

Roscoe C Young Jr, Raylinda E Rachal, Claude L Cowan Jr
PMCID: PMC2571364  PMID: 3783758

Abstract

About 80 percent of sarcoidosis cases are benign and do not require treatment, but 20 percent will have chronic unremitting disease for which therapy is essential. It is important that the physician identify this group and begin therapy promptly. If the disease is active, treat. If it is inactive, do not treat. Activity depends upon three major tests: serum angiotensin converting enzyme, gallium 67 scan, and bronchoalveolar lavage. The other consideration is involvement of vital organ systems; ie, active ocular disease, progressive pulmonary involvement as evidenced by increasing symptoms, impaired and deteriorating pulmonary function, or radiographic changes; hypercalcemia or hypercalciuria; central nervous system involvement; disfiguring cutaneous lesions; and myocardial sarcoidosis. Following a therapeutic decision to treat, adrenocorticoids are the drugs of choice. Methylprednisolone, prednisone, and cortisol are listed in order of benefit. Alternate day and/or low-dose steroids are increasing in popularity. Chloroquine phosphate is beneficial for skin lesions, while oxyphenbutazone has been found to be at least as effective as prednisone. Immunosuppressives may be used also. Chlorambucil and azathioprine have shown variable results. Cyclosporine (Cyclosporin A) shows promise and is now undergoing therapeutic trials.

Full text

PDF
811

Images in this article

812Figure 1
on p.812
812Figure 2
on p.812
815Figure 3
on p.815
816Figure 4
on p.816
817Figure 5
on p.817
818Figure 6
on p.818
819Figure 7
on p.819

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Israel H. L., Fouts D. W., Beggs R. A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973 Apr;107(4):609–614. doi: 10.1164/arrd.1973.107.4.609. [DOI] [PubMed] [Google Scholar]
  2. Israel H. L., Park C. H., Mansfield C. M. Gallium scanning in sarcoidosis. Ann N Y Acad Sci. 1976;278:514–516. doi: 10.1111/j.1749-6632.1976.tb47063.x. [DOI] [PubMed] [Google Scholar]
  3. Israel H. L. The treatment of sarcoidosis. Postgrad Med J. 1970 Aug;46(538):537–540. doi: 10.1136/pgmj.46.538.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Iwata K., Nanba K., Sobue K., Abe H. Ocular sarcoidosis: evaluation of intraocular findings. Ann N Y Acad Sci. 1976;278:445–454. doi: 10.1111/j.1749-6632.1976.tb47057.x. [DOI] [PubMed] [Google Scholar]
  5. JAMES D. G., ANDERSON R., LANGLEY D., AINSLIE D. OCULAR SARCOIDOSIS. Br J Ophthalmol. 1964 Sep;48:461–470. doi: 10.1136/bjo.48.9.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. James D. G., Carstairs L. S., Trowell J., Sharma O. P. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967 Sep 9;2(7515):526–528. doi: 10.1016/s0140-6736(67)90493-x. [DOI] [PubMed] [Google Scholar]
  7. Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Ann N Y Acad Sci. 1976;278:488–497. doi: 10.1111/j.1749-6632.1976.tb47061.x. [DOI] [PubMed] [Google Scholar]
  8. MORSE S. I., COHN Z. A., HIRSCH J. G., SCHAEDER R. W. The treatment of sarcoidosis with chloroquine. Am J Med. 1961 May;30:779–784. doi: 10.1016/0002-9343(61)90213-3. [DOI] [PubMed] [Google Scholar]
  9. Obenauf C. D., Shaw H. E., Sydnor C. F., Klintworth G. K. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol. 1978 Nov;86(5):648–655. doi: 10.1016/0002-9394(78)90184-8. [DOI] [PubMed] [Google Scholar]
  10. Osterberg G. IRITIS BOECK (SARKOID OF BOECK IN IRIS). Br J Ophthalmol. 1939 Mar;23(3):145–160. doi: 10.1136/bjo.23.3.145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sheagren J. N., Simon H. B., Rich R. R. Therapy of sarcoidosis initiated with alternate-day prednisone. J Natl Med Assoc. 1973 Sep;65(5):391–398. [PMC free article] [PubMed] [Google Scholar]
  12. Weinberger S. E., Kelman J. A., Elson N. A., Young R. C., Jr, Reynolds H. Y., Fulmer J. D., Crystal R. G. Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med. 1978 Oct;89(4):459–466. doi: 10.7326/0003-4819-89-4-459. [DOI] [PubMed] [Google Scholar]
  13. Young R. C., Jr, Carr C., Shelton T. G., Mann M., Ferrin A., Laurey J. R., Harden K. A. Sarcoidosis: relationship between changes in lung structure and function. Am Rev Respir Dis. 1967 Feb;95(2):224–238. doi: 10.1164/arrd.1967.95.2.224. [DOI] [PubMed] [Google Scholar]
  14. Young R. C., Jr, Rachal R. E., Cowan C. L., Jr Sarcoidosis--the beginning: historical highlights of personalities and their accomplishments during the early years. J Natl Med Assoc. 1984 Sep;76(9):887–896. [PMC free article] [PubMed] [Google Scholar]
  15. Young R. C., Jr, Sahetya G. K., Hassan S. N., Cobb W. B., Kumar B., Facen H. T. Chronic airways obstruction in pulmonary sarcoidosis: its poor response to bronchodilators. J Natl Med Assoc. 1980 Oct;72(10):965–972. [PMC free article] [PubMed] [Google Scholar]
  16. Young R. C., Jr, Titus-Dillon P. Y., Schneider M. L., Shelton T. G., Hackney R. L., Jr, Harden K. A. Sarcoidosis in Washington, D. C. Clinical observations in 105 black patients. Arch Intern Med. 1970 Jan;125(1):102–105. doi: 10.1001/archinte.125.1.102. [DOI] [PubMed] [Google Scholar]
  17. Young R. L., Harkleroad L. E., Lordon R. E., Weg J. G. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med. 1970 Aug;73(2):207–212. doi: 10.7326/0003-4819-73-2-207. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES